To read all of these articles and more, visit centerforbiosimilars.com.

Regulators and manufacturers advance biosimilars for aflibercept, omalizumab, and dupilumab, enhancing access to treatment in ...

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel ...

The debate over the Biosimilar Red Tape Elimination Act raises critical concerns about FDA standards, physician trust, and ...

A real-world study reveals that pediatric patients with IBD achieve high remission rates and cost savings using adalimumab ...

CT-P39, also known as Omlyclo, was approved by the European Medicines Agency in May 2025 as the first omalizumab biosimilar. 2 The biosimilar was also approved by Health Canada in December 2024 and ...